After review of safety and efficacy data, CymaBay Therapeutics stopped their Phase 2 study of MBX-8025 in Patients With Primary Biliary Cholangitis (PBC) early, due to data clearly demonstrating proof-of-concept by showing marked improvements in biochemical markers of cholestasis.
UK-PBC have worked closely with CymaBay Therapeutics throughout the study, including preliminary site identification, recruitment into the study and by utilising the UK-PBC Genetics Study Research Cohort and Consortium for potential patient identification.
You can read more about MBX-8025 on the CymaBay press release.
